Nordic Nanovector NOK0.20
Nordic Nanovector NOK0.20
2,73 %
32,36 NOK
0,86
Kurs
32,36
Hög
32,66
Förändring
2,73 %
Låg
31,50
Uppdaterad
2019-08-16
Öppen
31,50
Factsheet for Nordic Nanovector NOK0.20
Company Profile
Description
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin. Its product pipeline consists of chimeric, affilutin and NNV003 ARCs product candidates.
Key Stats
Website: http://www.nordicnanovector.com
Headquarter country: Norway
Employees: 14
Market Cap (at close 16-08-2019): NOK 2B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings
Forward Price/Earnings
Price/Free Cash Flow
Return on Assets -53,90 -32,20 -26,10 -31,30 -29,50
Return on Equity -64,80 -36,10 -28,30 -33,20 -31,10
Return on Invested Capital -65,70 -36,80 -28,90 -35,50 -33,40
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 0,00 0,30 0,31 0,44 0,44
Gross Profit -0,22
Gross Margin %
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -338,00 -315,00 -215,00 -182,00 -68,00
Net income -338,00 -294,00 -236,00 -173,00 -64,00
Basic Earnings Per Share -6,86 -5,97 -5,25 -4,27 -2,39
Operating Income -0,34 -0,32 -0,22 -0,18 -0,07
Operating Margin % -104 808,61% -68 905,10% -41 898,17% -15 642,37%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -327,00 -249,00 -170,00 -150,00 -58,00
Capital Expenditures -2,00 -3,00 -1,00 -2,00 -2,00
Free Cash Flow -329,00 -252,00 -172,00 -152,00 -60,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 469,50 776,30 1 041,59 757,56 344,09 85,64
Long Term Assets 4,08 4,17 3,15 2,81 1,62 0,38
Total Assets 473,59 780,47 1 044,74 760,37 345,71 86,02
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 107,02 97,24 95,45 47,63 15,50 7,24
Long Term Liabilities 0,00 0,00
Total Liabilities 95,45 47,63
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -296,41 -809,64 -514,08 -278,31 -105,20 -41,36
Treasury Stock
Total Stockholder Equity 363,19 679,61 949,29 712,74 330,21 78,79
Net Tangible Assets 363,19 679,59 949,03 712,21 329,79 78,79